
Global Uric Acid-lowering Drugs Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Uric Acid-lowering Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Uric Acid-lowering Drugs include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Uric Acid-lowering Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Uric Acid-lowering Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Uric Acid-lowering Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Uric Acid-lowering Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Uric Acid-lowering Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Uric Acid-lowering Drugs sales, projected growth trends, production technology, application and end-user industry.
Uric Acid-lowering Drugs Segment by Company
Takeda Pharmaceuticals
Teva
Sanwa Kagaku Kenkyusho
Sanofi
GSK
AstraZeneca
Towa Pharmaceutical
Toa Eiyo
Mylan Pharmaceuticals
Mochida Pharmaceutical
Lannett Company
Horizon Therapeutics
Fuji Yakuhin
Uric Acid-lowering Drugs Segment by Type
Uric Acid Production Inhibitors
Uric Acid Dissolving Agents
Urate-stimulating Excretion Agents
Uric Acid-lowering Drugs Segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Uric Acid-lowering Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Uric Acid-lowering Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Uric Acid-lowering Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
According to APO Research, The global Uric Acid-lowering Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Uric Acid-lowering Drugs include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Uric Acid-lowering Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Uric Acid-lowering Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Uric Acid-lowering Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Uric Acid-lowering Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Uric Acid-lowering Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Uric Acid-lowering Drugs sales, projected growth trends, production technology, application and end-user industry.
Uric Acid-lowering Drugs Segment by Company
Takeda Pharmaceuticals
Teva
Sanwa Kagaku Kenkyusho
Sanofi
GSK
AstraZeneca
Towa Pharmaceutical
Toa Eiyo
Mylan Pharmaceuticals
Mochida Pharmaceutical
Lannett Company
Horizon Therapeutics
Fuji Yakuhin
Uric Acid-lowering Drugs Segment by Type
Uric Acid Production Inhibitors
Uric Acid Dissolving Agents
Urate-stimulating Excretion Agents
Uric Acid-lowering Drugs Segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Uric Acid-lowering Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Uric Acid-lowering Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Uric Acid-lowering Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Uric Acid-lowering Drugs Market by Type
- 1.2.1 Global Uric Acid-lowering Drugs Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Uric Acid Production Inhibitors
- 1.2.3 Uric Acid Dissolving Agents
- 1.2.4 Urate-stimulating Excretion Agents
- 1.3 Uric Acid-lowering Drugs Market by Application
- 1.3.1 Global Uric Acid-lowering Drugs Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Hyperuricemia
- 1.3.3 Uric Acid Kidney Stones
- 1.3.4 Gout
- 1.3.5 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Uric Acid-lowering Drugs Market Dynamics
- 2.1 Uric Acid-lowering Drugs Industry Trends
- 2.2 Uric Acid-lowering Drugs Industry Drivers
- 2.3 Uric Acid-lowering Drugs Industry Opportunities and Challenges
- 2.4 Uric Acid-lowering Drugs Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Uric Acid-lowering Drugs Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Uric Acid-lowering Drugs Revenue by Region
- 3.2.1 Global Uric Acid-lowering Drugs Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Uric Acid-lowering Drugs Revenue by Region (2020-2025)
- 3.2.3 Global Uric Acid-lowering Drugs Revenue by Region (2026-2031)
- 3.2.4 Global Uric Acid-lowering Drugs Revenue Market Share by Region (2020-2031)
- 3.3 Global Uric Acid-lowering Drugs Sales Estimates and Forecasts 2020-2031
- 3.4 Global Uric Acid-lowering Drugs Sales by Region
- 3.4.1 Global Uric Acid-lowering Drugs Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Uric Acid-lowering Drugs Sales by Region (2020-2025)
- 3.4.3 Global Uric Acid-lowering Drugs Sales by Region (2026-2031)
- 3.4.4 Global Uric Acid-lowering Drugs Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Uric Acid-lowering Drugs Revenue by Manufacturers
- 4.1.1 Global Uric Acid-lowering Drugs Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Uric Acid-lowering Drugs Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Uric Acid-lowering Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Uric Acid-lowering Drugs Sales by Manufacturers
- 4.2.1 Global Uric Acid-lowering Drugs Sales by Manufacturers (2020-2025)
- 4.2.2 Global Uric Acid-lowering Drugs Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Uric Acid-lowering Drugs Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Uric Acid-lowering Drugs Sales Price by Manufacturers (2020-2025)
- 4.4 Global Uric Acid-lowering Drugs Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Uric Acid-lowering Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Uric Acid-lowering Drugs Manufacturers, Product Type & Application
- 4.7 Global Uric Acid-lowering Drugs Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Uric Acid-lowering Drugs Market CR5 and HHI
- 4.8.2 2024 Uric Acid-lowering Drugs Tier 1, Tier 2, and Tier 3
- 5 Uric Acid-lowering Drugs Market by Type
- 5.1 Global Uric Acid-lowering Drugs Revenue by Type
- 5.1.1 Global Uric Acid-lowering Drugs Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Uric Acid-lowering Drugs Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Uric Acid-lowering Drugs Revenue Market Share by Type (2020-2031)
- 5.2 Global Uric Acid-lowering Drugs Sales by Type
- 5.2.1 Global Uric Acid-lowering Drugs Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Uric Acid-lowering Drugs Sales by Type (2020-2031) & (Units)
- 5.2.3 Global Uric Acid-lowering Drugs Sales Market Share by Type (2020-2031)
- 5.3 Global Uric Acid-lowering Drugs Price by Type
- 6 Uric Acid-lowering Drugs Market by Application
- 6.1 Global Uric Acid-lowering Drugs Revenue by Application
- 6.1.1 Global Uric Acid-lowering Drugs Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Uric Acid-lowering Drugs Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Uric Acid-lowering Drugs Revenue Market Share by Application (2020-2031)
- 6.2 Global Uric Acid-lowering Drugs Sales by Application
- 6.2.1 Global Uric Acid-lowering Drugs Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Uric Acid-lowering Drugs Sales by Application (2020-2031) & (Units)
- 6.2.3 Global Uric Acid-lowering Drugs Sales Market Share by Application (2020-2031)
- 6.3 Global Uric Acid-lowering Drugs Price by Application
- 7 Company Profiles
- 7.1 Takeda Pharmaceuticals
- 7.1.1 Takeda Pharmaceuticals Comapny Information
- 7.1.2 Takeda Pharmaceuticals Business Overview
- 7.1.3 Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Takeda Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 7.1.5 Takeda Pharmaceuticals Recent Developments
- 7.2 Teva
- 7.2.1 Teva Comapny Information
- 7.2.2 Teva Business Overview
- 7.2.3 Teva Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Teva Uric Acid-lowering Drugs Product Portfolio
- 7.2.5 Teva Recent Developments
- 7.3 Sanwa Kagaku Kenkyusho
- 7.3.1 Sanwa Kagaku Kenkyusho Comapny Information
- 7.3.2 Sanwa Kagaku Kenkyusho Business Overview
- 7.3.3 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product Portfolio
- 7.3.5 Sanwa Kagaku Kenkyusho Recent Developments
- 7.4 Sanofi
- 7.4.1 Sanofi Comapny Information
- 7.4.2 Sanofi Business Overview
- 7.4.3 Sanofi Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Sanofi Uric Acid-lowering Drugs Product Portfolio
- 7.4.5 Sanofi Recent Developments
- 7.5 GSK
- 7.5.1 GSK Comapny Information
- 7.5.2 GSK Business Overview
- 7.5.3 GSK Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 GSK Uric Acid-lowering Drugs Product Portfolio
- 7.5.5 GSK Recent Developments
- 7.6 AstraZeneca
- 7.6.1 AstraZeneca Comapny Information
- 7.6.2 AstraZeneca Business Overview
- 7.6.3 AstraZeneca Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 AstraZeneca Uric Acid-lowering Drugs Product Portfolio
- 7.6.5 AstraZeneca Recent Developments
- 7.7 Towa Pharmaceutical
- 7.7.1 Towa Pharmaceutical Comapny Information
- 7.7.2 Towa Pharmaceutical Business Overview
- 7.7.3 Towa Pharmaceutical Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Towa Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 7.7.5 Towa Pharmaceutical Recent Developments
- 7.8 Toa Eiyo
- 7.8.1 Toa Eiyo Comapny Information
- 7.8.2 Toa Eiyo Business Overview
- 7.8.3 Toa Eiyo Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Toa Eiyo Uric Acid-lowering Drugs Product Portfolio
- 7.8.5 Toa Eiyo Recent Developments
- 7.9 Mylan Pharmaceuticals
- 7.9.1 Mylan Pharmaceuticals Comapny Information
- 7.9.2 Mylan Pharmaceuticals Business Overview
- 7.9.3 Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Mylan Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 7.9.5 Mylan Pharmaceuticals Recent Developments
- 7.10 Mochida Pharmaceutical
- 7.10.1 Mochida Pharmaceutical Comapny Information
- 7.10.2 Mochida Pharmaceutical Business Overview
- 7.10.3 Mochida Pharmaceutical Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Mochida Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 7.10.5 Mochida Pharmaceutical Recent Developments
- 7.11 Lannett Company
- 7.11.1 Lannett Company Comapny Information
- 7.11.2 Lannett Company Business Overview
- 7.11.3 Lannett Company Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Lannett Company Uric Acid-lowering Drugs Product Portfolio
- 7.11.5 Lannett Company Recent Developments
- 7.12 Horizon Therapeutics
- 7.12.1 Horizon Therapeutics Comapny Information
- 7.12.2 Horizon Therapeutics Business Overview
- 7.12.3 Horizon Therapeutics Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Horizon Therapeutics Uric Acid-lowering Drugs Product Portfolio
- 7.12.5 Horizon Therapeutics Recent Developments
- 7.13 Fuji Yakuhin
- 7.13.1 Fuji Yakuhin Comapny Information
- 7.13.2 Fuji Yakuhin Business Overview
- 7.13.3 Fuji Yakuhin Uric Acid-lowering Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Fuji Yakuhin Uric Acid-lowering Drugs Product Portfolio
- 7.13.5 Fuji Yakuhin Recent Developments
- 8 North America
- 8.1 North America Uric Acid-lowering Drugs Market Size by Type
- 8.1.1 North America Uric Acid-lowering Drugs Revenue by Type (2020-2031)
- 8.1.2 North America Uric Acid-lowering Drugs Sales by Type (2020-2031)
- 8.1.3 North America Uric Acid-lowering Drugs Price by Type (2020-2031)
- 8.2 North America Uric Acid-lowering Drugs Market Size by Application
- 8.2.1 North America Uric Acid-lowering Drugs Revenue by Application (2020-2031)
- 8.2.2 North America Uric Acid-lowering Drugs Sales by Application (2020-2031)
- 8.2.3 North America Uric Acid-lowering Drugs Price by Application (2020-2031)
- 8.3 North America Uric Acid-lowering Drugs Market Size by Country
- 8.3.1 North America Uric Acid-lowering Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Uric Acid-lowering Drugs Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Uric Acid-lowering Drugs Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 9 Europe
- 9.1 Europe Uric Acid-lowering Drugs Market Size by Type
- 9.1.1 Europe Uric Acid-lowering Drugs Revenue by Type (2020-2031)
- 9.1.2 Europe Uric Acid-lowering Drugs Sales by Type (2020-2031)
- 9.1.3 Europe Uric Acid-lowering Drugs Price by Type (2020-2031)
- 9.2 Europe Uric Acid-lowering Drugs Market Size by Application
- 9.2.1 Europe Uric Acid-lowering Drugs Revenue by Application (2020-2031)
- 9.2.2 Europe Uric Acid-lowering Drugs Sales by Application (2020-2031)
- 9.2.3 Europe Uric Acid-lowering Drugs Price by Application (2020-2031)
- 9.3 Europe Uric Acid-lowering Drugs Market Size by Country
- 9.3.1 Europe Uric Acid-lowering Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Uric Acid-lowering Drugs Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Uric Acid-lowering Drugs Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
- 10 China
- 10.1 China Uric Acid-lowering Drugs Market Size by Type
- 10.1.1 China Uric Acid-lowering Drugs Revenue by Type (2020-2031)
- 10.1.2 China Uric Acid-lowering Drugs Sales by Type (2020-2031)
- 10.1.3 China Uric Acid-lowering Drugs Price by Type (2020-2031)
- 10.2 China Uric Acid-lowering Drugs Market Size by Application
- 10.2.1 China Uric Acid-lowering Drugs Revenue by Application (2020-2031)
- 10.2.2 China Uric Acid-lowering Drugs Sales by Application (2020-2031)
- 10.2.3 China Uric Acid-lowering Drugs Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Uric Acid-lowering Drugs Market Size by Type
- 11.1.1 Asia Uric Acid-lowering Drugs Revenue by Type (2020-2031)
- 11.1.2 Asia Uric Acid-lowering Drugs Sales by Type (2020-2031)
- 11.1.3 Asia Uric Acid-lowering Drugs Price by Type (2020-2031)
- 11.2 Asia Uric Acid-lowering Drugs Market Size by Application
- 11.2.1 Asia Uric Acid-lowering Drugs Revenue by Application (2020-2031)
- 11.2.2 Asia Uric Acid-lowering Drugs Sales by Application (2020-2031)
- 11.2.3 Asia Uric Acid-lowering Drugs Price by Application (2020-2031)
- 11.3 Asia Uric Acid-lowering Drugs Market Size by Country
- 11.3.1 Asia Uric Acid-lowering Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Uric Acid-lowering Drugs Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Uric Acid-lowering Drugs Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Uric Acid-lowering Drugs Market Size by Type
- 12.1.1 SAMEA Uric Acid-lowering Drugs Revenue by Type (2020-2031)
- 12.1.2 SAMEA Uric Acid-lowering Drugs Sales by Type (2020-2031)
- 12.1.3 SAMEA Uric Acid-lowering Drugs Price by Type (2020-2031)
- 12.2 SAMEA Uric Acid-lowering Drugs Market Size by Application
- 12.2.1 SAMEA Uric Acid-lowering Drugs Revenue by Application (2020-2031)
- 12.2.2 SAMEA Uric Acid-lowering Drugs Sales by Application (2020-2031)
- 12.2.3 SAMEA Uric Acid-lowering Drugs Price by Application (2020-2031)
- 12.3 SAMEA Uric Acid-lowering Drugs Market Size by Country
- 12.3.1 SAMEA Uric Acid-lowering Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Uric Acid-lowering Drugs Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Uric Acid-lowering Drugs Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Uric Acid-lowering Drugs Value Chain Analysis
- 13.1.1 Uric Acid-lowering Drugs Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Uric Acid-lowering Drugs Production Mode & Process
- 13.2 Uric Acid-lowering Drugs Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Uric Acid-lowering Drugs Distributors
- 13.2.3 Uric Acid-lowering Drugs Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.